tiprankstipranks
KalVista Pharmaceuticals (DE:4XC1)
FRANKFURT:4XC1
Germany Market

KalVista Pharmaceuticals (4XC1) Income Statement

Compare
0 Followers

KalVista Pharmaceuticals Income Statement

Last quarter (Q2 2025), KalVista Pharmaceuticals's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q2, KalVista Pharmaceuticals's net income was $-42.27M. See KalVista Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Jun 24Jun 23Jun 22Jun 21Jun 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 12.69M$ 12.69M
Gross Profit
$ -86.17M$ -802.00K$ -743.00K$ 12.04M$ 12.65M
Operating Expenses
$ 54.28M$ 110.87M$ 96.61M$ 57.92M$ 53.22M
Depreciation and Amortization
$ 816.00K$ 802.00K$ 743.00K$ 651.00K$ 525.00K
EBITDA
$ -134.28M$ -92.11M$ -81.60M$ -45.59M$ -40.02M
Operating Income
$ -140.44M$ -110.87M$ -96.61M$ -57.92M$ -40.53M
Other Income/Expenses
$ 5.35M$ 17.96M$ 14.27M$ 11.68M$ 11.29M
Pretax Income
$ -135.10M$ -92.91M$ -82.34M$ -46.24M$ -29.24M
Net Income
$ -126.64M$ -74.85M$ -68.51M$ -44.49M$ -29.12M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -3.44$ -2.68$ -2.80$ -2.33$ -1.64
Diluted EPS
$ -3.44$ -2.68$ -2.80$ -2.33$ -1.64
Weighted Average Shares Outstanding
36.79M 27.89M 24.47M 19.09M 17.75M
Weighted Average Shares Outstanding (Diluted)
36.79M 27.89M 24.47M 19.09M 17.75M
Currency in USD

KalVista Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis